1416507-12-4

Basic information

• Product Name: C₃₀H₂₉NO₄
• Synonyms: C₃₀H₂₉NO₄
• CAS NO: 1416507-12-4
• Molecular Weight: 467.565
• Mol File: 1416507-12-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₃₀H₂₉NO₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₀H₂₉NO₄(1416507-12-4)
• EPA Substance Registry System: C₃₀H₂₉NO₄(1416507-12-4)

Safety Data

• Hazardous Substances Data: 1416507-12-4(Hazardous Substances Data)

Upstream product

• 1416324-27-0 (2R,3R,7S)-7-(bromomethyl)-7-methyl-2,3-diphenyl-1,4-dioxaspiro[4.5]decane 
• 1416324-25-8 (2R,3R)-7-methyl-2,3-diphenyl-1,4-dioxaspiro[4.5]dec-6-ene 
• 1416324-26-9 (1S,4'R,5'R,6R)-6-methyl-4',5'-diphenylspiro[bicyclo[4.1.0]heptane-2,2'-[1,3]dioxolane] 
• 1193-18-6 3-methylcyclohexen-2-one 
• 52340-78-0 (R,R)-hydroxybenzoin 
• 1074-82-4 potassium phtalimide 

Downstream Products

• 1416324-28-1 {[(2R,3R,7S)-7-methyl-2,3-diphenyl-1,4-dioxaspiro[4.5]dec-7-yl]methyl}amine 
• 1416324-29-2 3-({[(2R,3R,7S)-7-methyl-2,3-diphenyl-1,4-dioxaspiro[4,5]dec-7-yl]methyl}amino)-4-nitrobenzonitrile 
• 1416324-30-5 1-{[(2R,3R,7S)-7-methyl-2,3-diphenyl-1,4-dioxaspiro[4,5]dec-7-yl]methyl}-1H-benzimidazole-6-carbonitrile 
• 1416324-31-6 1-{[(1S)-1-methyl-3-oxocyclohexaneyl]methyl}-1H-benzimidazole-6-carbonitrile 
• 1416324-71-4 1-{[(3S,5S)-3-hydroxy-3-(hydroxymethyl)-1-methylcyclohexaneyl]methyl}-1H-benzimidazole-6-carbonitrile 
• 1416323-43-7 1-({(5S,7S)-3-[4-(ethyloxy)phenyl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]dec-7-yl}methyl)-1H-benzimidazole-6-carbonitril 

Relevant articles and documents

Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4)

GSK2798745, a clinical candidate, was identified as an inhibitor of the transient receptor potential vanilloid 4 (TRPV4) ion channel for the treatment of pulmonary edema associated with congestive heart failure. We discuss the lead optimization of this novel spirocarbamate series and specifically focus on our strategies and solutions for achieving desirable potency, rat pharmacokinetics, and physicochemical properties. We highlight the use of conformational bias to deliver potency and optimization of volume of distribution and unbound clearance to enable desirable in vivo mean residence times.